Literature DB >> 10799884

Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.

P I Karachunski1, N S Ostlie, C Monfardini, B M Conti-Fine.   

Abstract

Immunization with acetylcholine receptor (AChR) causes experimental myasthenia gravis (EMG). Th1 cells facilitate EMG development. IFN-gamma and IL-12 induce Th1 responses: we investigated whether these cytokines are necessary for EMG development. We immunized wild-type (WT) C57BL/6 mice and IFN-gamma and IL-12 knockout mutants (IFN-gamma-/-, IL-12-/-) with Torpedo AChR (TAChR). WT and IFN-gamma-/- mice developed EMG with similar frequency, IL-12-/-mice were resistant to EMG. All strains synthesized anti-AChR Ab that were not IgM or IgE. WT mice had anti-AChR IgG1, IgG2b, and IgG2c, IFN-gamma-/- mice had significantly less IgG2c, and IL-12-/- mice less IgG2b and IgG2c. All mice had IgG bound to muscle synapses, but only WT and IFN-gamma-/- mice had complement; WT mice had both IgG2b and IgG2c, IFN-gamma-/- only IgG2b, and IL-12-/- neither IgG2b nor IgG2c. CD4+ cells from all AChR-immunized mice proliferated in response to AChR and recognized similar epitopes. After stimulation with TAChR, CD4+ cells from IFN-gamma-/- mice secreted less IL-2 and similar amounts of IL-4 and IL-10 as WT mice. CD4+ cells from IL-12-/- mice secreted less IFN-gamma, but more IL-4 and IL-10 than WT mice, suggesting that they developed a stronger Th2 response to TAChR. The EMG resistance of IL-12-/- mice is likely due to both reduction of anti-TAChR Ab that bind complement and sensitization of modulatory Th2 cells. The reduced Th1 function of IFN-gamma-/- mice does not suffice to reduce all complement-fixing IgG subclasses, perhaps because as in WT mice a protective Th2 response is missing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799884     DOI: 10.4049/jimmunol.164.10.5236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

2.  Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice.

Authors:  K Kitagaki; T R Businga; J N Kline
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Protective neutralizing influenza antibody response in the absence of T follicular helper cells.

Authors:  Kosuke Miyauchi; Akiko Sugimoto-Ishige; Yasuyo Harada; Yu Adachi; Yoshiko Usami; Tomohiro Kaji; Kentaro Inoue; Hideki Hasegawa; Takashi Watanabe; Atsushi Hijikata; Satoshi Fukuyama; Tadashi Maemura; Mariko Okada-Hatakeyama; Osamu Ohara; Yoshihiro Kawaoka; Yoshimasa Takahashi; Toshitada Takemori; Masato Kubo
Journal:  Nat Immunol       Date:  2016-10-31       Impact factor: 25.606

5.  Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis.

Authors:  D Yarilin; R Duan; Y-M Huang; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 6.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

7.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.

Authors:  Wei Wang; Monica Milani; Norma Ostlie; David Okita; Rajeev K Agarwal; Rachel R Caspi; Rachel Caspi; Bianca M Conti-Fine
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

8.  Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats.

Authors:  Chenjing Sun; Hongliang Zhang; Jiang Xu; Jie Gao; Xiaokun Qi; Zhuyi Li
Journal:  Arch Med Sci       Date:  2013-08-12       Impact factor: 3.318

9.  Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Authors:  Sam D Sanderson; Marilyn L Thoman; Kornelia Kis; Elizabeth L Virts; Edgar B Herrera; Stephanie Widmann; Homero Sepulveda; Joy A Phillips
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis.

Authors:  Chang-Suk Chae; Ho-Keun Kwon; Ji-Sun Hwang; Jung-Eun Kim; Sin-Hyeog Im
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.